VanEck Associates’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

VanEck Associates’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,153	Closed	-$65K	–	1393
2026 Q1	$65K	Buy	2,153 +185	+9%	+$6.13K	﹤0.01%	1325
2025 Q4	$64K	Buy	1,968 +750	+62%	+$24.2K	﹤0.01%	1343
2025 Q3	$42K	Buy	1,218 +107	+10%	+$3.42K	﹤0.01%	1349
2025 Q2	$31K	Hold	1,111	–	–	﹤0.01%	1339
2025 Q1	$28K	Sell	1,111 -42	-4%	-$1.06K	﹤0.01%	1324
2024 Q4	$32K	Buy	1,153 +400	+53%	+$11.2K	﹤0.01%	1316
2024 Q3	$23K	Sell	753 -456	-38%	-$12.4K	﹤0.01%	1308
2024 Q2	$30K	Hold	1,209	–	–	﹤0.01%	1313
2024 Q1	$39K	Buy	1,209 +62	+5%	+$2.31K	﹤0.01%	1290
2023 Q4	$47K	Buy	1,147 +191	+20%	+$7.03K	﹤0.01%	1287
2023 Q3	$33K	Hold	956	–	–	﹤0.01%	1311
2023 Q2	$39K	Hold	956	–	–	﹤0.01%	1313
2023 Q1	$37K	Sell	956 -42	-4%	-$1.73K	﹤0.01%	1325
2022 Q4	$44K	Buy	998 +230	+30%	+$9.7K	﹤0.01%	1324
2022 Q3	$33K	Buy	+768	New	+$39.4K	﹤0.01%	1292

Other funds holding LKFT

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

VanEck Associates's LKFT Position: Q2 2026 in Review

VanEck Associates sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q2 2026, closing a stake of 2,153 shares — an estimated $65K sold.

VanEck Associates first reported a position in LKFT in Q3 2022 and held it in 15 quarters. The position peaked at $65K in Q1 2026. 76 funds tracked by Wall St. Rank hold LKFT as of Q2 2026.

VanEck Associates reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q2 2026 after selling out during the quarter.
VanEck Associates sold 2,153 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2026, an estimated $65K.
VanEck Associates first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2022 and held it in 15 quarters.
VanEck Associates's Lakefront Biotherapeutics American Depositary Shares position peaked at $65K in Q1 2026.
76 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2026.

Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.